Last reviewed · How we verify
Colaren in HIV negative
Colaren is an investigational drug that targets the HIV virus.
Colaren is an investigational drug that targets the HIV virus. Used for HIV infection.
At a glance
| Generic name | Colaren in HIV negative |
|---|---|
| Also known as | plus Zoledronic Acid 4 mg |
| Sponsor | University of Guadalajara |
| Drug class | Antiretroviral |
| Target | HIV |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Colaren works by binding to the HIV virus, preventing it from replicating in the body. This mechanism of action is similar to other antiretroviral drugs, but the exact details of Colaren's mechanism are not well understood.
Approved indications
- HIV infection
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colaren in HIV negative CI brief — competitive landscape report
- Colaren in HIV negative updates RSS · CI watch RSS
- University of Guadalajara portfolio CI